Glucagon-like peptide-1 (GLP-1) regulates islet function by enhancing glucose-stimulated insulin secretion (GSIS). We previously found that the beta cell GLP-1 receptor (GLP-1R) contributes to improvements in glucose regulation and islet function in mice that have undergone bariatric surgery, specifically, vertical sleeve gastrectomy (VSG). Further investigation revealed that VSG increases alpha cell GLP-1 production by turning on the expression of prohormone convertase 1/3 (PC1/3, gene: Pcsk1) in a beta cell GLP-1R-dependent fashion. These findings lead us to hypothesize that beta cell GLP-1R signaling increases alpha cell GLP-1 production to augment GSIS in a paracrine positive feedback loop. In the current study, we tested whether the effects of VSG can be recapitulated by pharmacologic stimulation of the GLP-1R, using a GLP-1 analog, liraglutide. We found that liraglutide treatment increases alpha cell GLP-1 expression in a beta cell GLP-1R dependent fashion (GLP-1 area per islet (µm2): Vehicle WT = 132 ± 3, Vehicle KO = 73 ± 2, Liraglutide WT = 241 ± 15, Liraglutide KO = 67 ± 1; P<0.05 Liraglutide WT vs. all groups). We then used an innovative single-cell RNA-sequencing platform, DART-seq, to determine the translational relevance of this new model of islet function. We validated application of DART-seq in human islets, and using this technology we observed that liraglutide induces a 1.5 log-fold increase in Pcsk1 mRNA expression compared with saline treated controls in a subset of alpha cells (P<0.05 saline vs. liraglutide). Additionally, our DART-seq data suggests that liraglutide-induced increase in alpha cell PC1/3 expression may be part of a broader induction of alpha-cell transdifferentiation to beta cells. Thus, our study demonstrates that the effect of beta cell GLP-1R signaling to increase alpha-cell GLP-1 expression can be stimulated by pharmacological activation of the GLP-1R and has translational relevance in humans.

Disclosure

M. Saikia: None. M.M. Holter: None. D. Garibay: None. A. Garcia-Ocana: None. C.G. Danko: None. B. Cummings: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.